About this trial
The purpose of this research study is to find out whether women with severe preeclampsia taking low-dose aspirin (LDA) for 3 weeks post-delivery will experience an improvement in endothelial function (measured as flow-mediated dilation - FMD) and severity of disease, as the effects of preeclampsia can persist postpartum. Women diagnosed with severe preeclampsia prior to delivery will be enrolled and randomized to receive either low-dose aspirin (81mg) or placebo to take daily for up to 3 weeks post-delivery. Exploratory objective includes healthy control postpartum patients without preeclampsia and not on LDA during pregnancy or postpartum in comparison with the primary study population affected by preeclampsia with severe features.
Eligibility criteria
Qualifiers
Singleton or Multiple gestation
Maternal age >= 18 years
20 0/7 weeks gestation or greater
Severe Preeclampsia diagnosed prior to delivery
Disqualifiers
Aspirin use postpartum for other medical indication
Lovenox, unfractionated heparin, or other anticoagulant use postpartum for an indication other than postoperative (in-house)
Aspirin use within 7 days of planned initial FMD testing postpartum
Hypersensitivity or allergy to Aspirin or other salicylates
Trial design
Treatments tested in this trial
- Aspirin tablet
- Placebo oral capsule